Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 28 min ago
Peer-reviewedLicence not statedThe Lancet. Haematology

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial

  • Jeremy S. Abramson1
  • Susan Geyer2
  • Sharmila Giri2,3
  • Levi Pederson2,3
  • Ann Hudson2,3
  • Eric D. Hsi3
  • Neha Mehta-Shah4
  • Patrick M. Reagan5
  • Richard L. Deming6
  • Richard F. Little7
  • Steven Gore7
  • Shira N. Dinner8
6 more authors
  • Anusha Vallurupalli9
  • Daniel J. Landsburg10
  • Brad Kahl4
  • Jonathan W. Friedberg5
  • Nancy L. Bartlett4
  • John P. Leonard11
11 affiliations
  1. 1Massachusetts General Hospital, Boston, MA
  2. 2Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN
  3. 3Mayo Clinic, Rochester, MN
  4. 4Washington University School of Medicine, St. Louis, MO
  5. 5University of Rochester, Rochester, NY
  6. 6UI Health Care Mission Cancer and Blood, Des Moines, IA
  7. 7National Cancer Institute, Rockville, MD
  8. 8Northwestern University, Chicago, IL
  9. 9University of Kansas Medical Center, Kansas City, KS
  10. 10University of Pennsylvania, Philadelphia, PA
  11. 11Weill Cornell Medicine, New York, NY
Read full textPDFDOICite

Related

  1. Infection Profiles Under Venetoclax‐Based Therapy in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study
    Guilin Ren, Guangyu Zhou, Hao Zhou +8
    Cancer medicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy
    Qi Chen, Wenbing Duan, Jinsong Jia +7
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Lymphomas Diagnosed Primarily on Serous Effusion Cytology: Cytology Rises to the Challenge!
    Vinamrata Soni, Satarupa Samanta, Majal C Dharaiya +3
    Journal of cytologyPeer-reviewedCC BY-NC-SAFull textCell biologyGeneral medicineEurope PMCDOAJ
  4. Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia
    Hui-Fang Liu, Cheng Lian, Xian-Guang Zhu
    BMC GeriatricsPeer-reviewedCC BYFull textGeneral medicineDOAJ
  5. Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia
    J.-N. Eckardt, I. Srivastava, K. Gill +12
    medRxivPreprintCC BY-NC-NDFull textGeneral medicinemedRxiv

Cite

BibTeXRIS
BibTeX
@article{abramson2026venetoclax,
  title = {{Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial}},
  author = {Jeremy S. Abramson and Susan Geyer and Sharmila Giri and Levi Pederson and Ann Hudson and Eric D. Hsi and Neha Mehta-Shah and Patrick M. Reagan and Richard L. Deming and Richard F. Little and Steven Gore and Shira N. Dinner and Anusha Vallurupalli and Daniel J. Landsburg and Brad Kahl and Jonathan W. Friedberg and Nancy L. Bartlett and John P. Leonard},
  journal = {The Lancet. Haematology},
  year = {2026},
  month = nov,
  doi = {10.1016/s2352-3026(26)00191-2},
  url = {https://doi.org/10.1016/s2352-3026(26)00191-2},
}
RIS
TY  - JOUR
TI  - Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial
AU  - Jeremy S. Abramson
AU  - Susan Geyer
AU  - Sharmila Giri
AU  - Levi Pederson
AU  - Ann Hudson
AU  - Eric D. Hsi
AU  - Neha Mehta-Shah
AU  - Patrick M. Reagan
AU  - Richard L. Deming
AU  - Richard F. Little
AU  - Steven Gore
AU  - Shira N. Dinner
AU  - Anusha Vallurupalli
AU  - Daniel J. Landsburg
AU  - Brad Kahl
AU  - Jonathan W. Friedberg
AU  - Nancy L. Bartlett
AU  - John P. Leonard
PY  - 2026
DA  - 2026/11/04
JO  - The Lancet. Haematology
DO  - 10.1016/s2352-3026(26)00191-2
UR  - https://doi.org/10.1016/s2352-3026(26)00191-2
SN  - 2352-3026
ER  -